Myriad Genetics
MYGN
205 hedge funds and large institutions have $1.98B invested in Myriad Genetics in 2022 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 65 increasing their positions, 74 reducing their positions, and 22 closing their positions.
785% more call options, than puts
Call options by funds: $7.18M | Put options by funds: $811K
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
4% more funds holding
Funds holding: 197 → 205 (+8)
0.53% more ownership
Funds ownership: 98.03% → 98.56% (+0.53%)
8% less capital invested
Capital invested by funds: $2.16B → $1.98B (-$175M)
12% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.7M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$19.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.22M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.91M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$22.7M |
| 2 |
Goldman Sachs
New York
|
-$7.08M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.48M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.43M |
MYGN Hedge Fund Activity: Q1 2022 in Review
205 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2022, worth a combined $1.98B — down 8.1% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new MYGN positions and 22 closed out — a net gain of 9 holders — while 65 added to existing stakes and 74 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $19.7M. The largest seller was Millennium Management, cutting an estimated $22.7M.
- 205 institutional investors held Myriad Genetics (MYGN) as of Q1 2022, up from 197 in Q4 2021.
- Funds reported $1.98B of Myriad Genetics stock for Q1 2022, down 8.1% quarter-over-quarter.
- 31 funds opened new Myriad Genetics positions in Q1 2022 and 22 closed out, a net change of +9 holders.
- The largest Myriad Genetics buyer in Q1 2022 was Wellington Management Group, an estimated $19.7M added.
- The largest Myriad Genetics seller in Q1 2022 was Millennium Management, an estimated $22.7M sold.
Based on aggregated 13F filings for Q1 2022.